Can a patient develop a pulmonary embolism despite being on therapeutic anticoagulation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Can You Develop a Pulmonary Embolism on Anticoagulants?

Yes, patients can develop pulmonary embolism despite being on therapeutic anticoagulation, though this occurs in only about 1-2% of cases, and when it happens, you must immediately escalate therapy with rescue thrombolysis if hemodynamically unstable or switch/intensify anticoagulation regimens if stable. 1, 2

When PE Occurs Despite Anticoagulation

The 2019 ESC Guidelines explicitly address this scenario: administer rescue thrombolytic therapy to patients with hemodynamic deterioration on anticoagulation treatment 1. This is a Class I recommendation, meaning it's the definitive action when a patient on anticoagulation develops high-risk PE with shock or hypotension.

Key Clinical Scenarios

For hemodynamically unstable patients:

  • Immediate systemic thrombolysis is indicated regardless of current anticoagulation status
  • If thrombolysis is contraindicated or fails, proceed to surgical pulmonary embolectomy 1

For hemodynamically stable patients:

  • Reassess anticoagulation adequacy immediately
  • Check for subtherapeutic levels (particularly INR <2.0 for warfarin patients) 2
  • Verify medication adherence
  • Consider switching anticoagulant class (e.g., warfarin to DOAC or vice versa) 2

Why This Happens

Common Causes of Breakthrough PE:

  1. Subtherapeutic anticoagulation - Most common cause. In one study, 42% of patients with PE on warfarin had at least one subtherapeutic INR (<2.0) in the preceding 14 days 2

  2. Warfarin variability - Multiple factors affect warfarin's therapeutic effect, making DOACs more reliable in many patients 3

  3. Severe inflammatory states - Particularly COVID-19 pneumonia, where local vascular damage from viral infection triggers in-situ thrombosis rather than embolic events 4, 5

  4. Active cancer - Creates a prothrombotic state that can overwhelm standard anticoagulation 1

  5. Antiphospholipid antibody syndrome - These patients specifically require VKAs (not DOACs) and may need higher intensity anticoagulation 1

Critical Management Algorithm

Step 1: Assess hemodynamic stability

  • Hypotension (SBP <90 mmHg) or shock → Give thrombolysis immediately 1
  • Stable → Proceed to Step 2

Step 2: Verify therapeutic anticoagulation

  • Check INR if on warfarin (therapeutic = 2.0-3.0)
  • Review medication adherence
  • Check renal function (affects DOAC levels, especially with severe impairment) 1

Step 3: Identify underlying cause

  • Active cancer present?
  • Antiphospholipid antibodies?
  • Severe inflammatory state (sepsis, COVID-19)?
  • Recent subtherapeutic levels?

Step 4: Modify anticoagulation

  • If on warfarin with variable INRs → Switch to DOAC (unless contraindicated) 3
  • If on DOAC → Consider switching to different DOAC or adding parenteral anticoagulation temporarily 2
  • If antiphospholipid syndrome → Must use VKA, consider higher intensity (INR 2.5-3.5) 1
  • Consider adding inferior vena cava filter only in specific circumstances (not routine) 1

Important Caveats

Do not assume anticoagulation provides complete protection. Even patients on dual therapy (anticoagulation plus antiplatelet) can develop PE 3. The presence of anticoagulation should never lower your clinical suspicion if PE symptoms are present.

DOACs are generally superior to warfarin for preventing breakthrough events due to more predictable pharmacokinetics, but they are absolutely contraindicated in:

  • Severe renal impairment (CrCl <30 mL/min for most DOACs)
  • Antiphospholipid antibody syndrome 1
  • Pregnancy 1

COVID-19 creates unique risk. Multiple case series show PE occurring despite therapeutic anticoagulation in severe COVID-19 pneumonia, likely due to inflammation-mediated in-situ pulmonary thrombosis rather than traditional embolic disease 4, 5. These patients may require more aggressive anticoagulation strategies.

Recurrent VTE on anticoagulation mandates indefinite treatment. If a patient develops PE while on appropriate anticoagulation, they require lifelong anticoagulation unless a major reversible risk factor is identified 1.

Monitoring After Breakthrough PE

Once anticoagulation is modified, reassess at regular intervals:

  • Drug tolerance and adherence
  • Hepatic and renal function
  • Bleeding risk assessment
  • Consider reduced-dose DOAC after 6 months if using apixaban 2.5 mg twice daily or rivaroxaban 10 mg daily for extended prophylaxis 1

The bottom line: Anticoagulation reduces but does not eliminate PE risk. When breakthrough PE occurs, escalate therapy based on hemodynamic status and investigate why anticoagulation failed.

References

Related Questions

Which oral anticoagulant is recommended for outpatient treatment of acute pulmonary embolism in an otherwise healthy adult?
What is the recommended anticoagulation regimen for an acute pulmonary embolism?
What examinations should be ordered to rule out pulmonary embolism in the emergency department?
In a 38-year-old woman with persistent dyspnea four months after an acute pulmonary embolism treated with three months of anticoagulation, which test should be ordered next: a 6‑minute walk test, CT pulmonary angiography, ventilation‑perfusion (V/Q) lung scan, or pulmonary angiography?
What are the 2026 guidelines for the management of pulmonary embolism?
In a patient on lisinopril 10 mg daily and amlodipine 10 mg daily who now has hypotension (BP 95/36 mmHg), what should be done?
What is the recommended acetaminophen (paracetamol) dosage for a typical adult without hepatic impairment?
What could be causing an itchy throat, dizziness, nausea, epigastric burning, and intermittent fever?
How are clinical injuries that occur during percutaneous nephrolithotomy (PCNL) managed?
What is the recommended management for low ferritin?
Is arthroscopic capsular release appropriate for bilateral adhesive capsulitis unresponsive to eight months of conservative therapy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.